Kyverna Therapeutics, INC. 8-K Filing

Ticker: KYTX · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1994702

Sentiment: neutral

Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-14 06:12:00

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 14, 2024, Kyverna Therapeutics, Inc. (the "Company") hosted an industry symposium at EULAR in Vienna with a data update on KYV-101, its lead CAR T-cell therapy candidate. A copy of the Company's presentation is being furnished as Exhibit 99.1. The Company's presentation is current as of June 14, 2024, and the Company disclaims any obligation to update this material in the future. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Presentation - Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond, dated June 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: June 14, 2024 By: /s/ Ryan Jones Name: Ryan Jones Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing